Primary research partner

Institute for Microcirculation, Berlin

BEMER's core research was developed in collaboration with the Institute for Microcirculation (IfM) in Berlin — a specialist research institute focused on the physiology of small blood vessels and the mechanisms that govern blood flow through capillaries, arterioles, and venules.

The IfM's work established the scientific basis for BEMER's patented signal: a specific electromagnetic waveform calibrated to stimulate vasomotion — the rhythmic contraction and relaxation of small blood vessel walls that drives microcirculatory flow. This mechanism distinguishes BEMER from generic pulsed electromagnetic field (PEMF) devices, which do not target vasomotion specifically.

The collaboration produced peer-reviewed publications demonstrating measurable improvements in local microcirculatory blood flow following BEMER application — with independent studies recording increases of up to 29% after a single 8-minute session.

Institutional Agreement — 2015

NASA Space Act Agreement.

NASA and BEMER have signed a cooperation agreement that governs the joint development of a prototype of a space suit, which improves microcirculation while preventing bone and muscle atrophy during space missions. It should also assist recuperation after space travel.

The agreement was signed in 2015 between NASA's Lyndon B. Johnson Space Center and BEMER USA. The mechanism under investigation — vasomotion-optimising microcirculatory support — is the same technology used in BEMER's consumer devices. This is a research and development cooperation, not a product endorsement.

Regulatory status

Class IIa medical device — European registration.

BEMER is registered as a Class IIa medical device under European CE marking requirements — the same regulatory tier as surgical instruments, infusion pumps, and diagnostic ultrasound equipment. Class IIa registration requires demonstrated clinical evidence of safety and efficacy under EU Medical Device Regulation (MDR 2017/745).

This is not a consumer wellness claim. BEMER is manufactured to medical device standards, with documented quality management and post-market surveillance — the same framework that applies to regulated medical equipment globally.

Clinical research areas

What the research covers.

Published and ongoing research on BEMER covers a wide range of clinical applications, with the strongest evidence base in conditions where microcirculatory dysfunction is a primary mechanism:

Professional use

Used by professional sports teams and medical practitioners.

BEMER is used by professional and elite sports teams across Europe and internationally — including football clubs, cycling teams, and Olympic training programmes. The performance and recovery benefits documented in clinical research translate directly to athletic application: faster muscle recovery, reduced soreness, and better sleep between training sessions.

It is also used by physiotherapists, rehabilitation specialists, and integrative medicine practitioners in clinical settings across 43 countries — not as a replacement for medical treatment, but as an adjunct that addresses the microvascular dimension of recovery and chronic disease management.